SCHEMBL13006754

SCHEMBL13006754

CNc1ccc(-c2ccc(C#N)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 1/20 0.52
KIF11 P52732 3/20 0.52
APP P05067 2/20 0.51
LOXL2 Q9Y4K0 1/20 0.48
ALDH1A1 P00352 3/20 0.46
CYP2A6 P11509 1/20 0.46
MAPT P10636 1/20 0.45
ABCB1 P08183 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
HSD11B1 P28845 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP11B2 P19099 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360149 0.93 LOXL2 (0.54) APPLOXL2ALDH1A1CYP2A6MAPT
Hydrochloric Acid SCHEMBL27473265 0.91 ALDH1A1 (0.54) APPLOXL2ALDH1A1CYP2A6MAPT
Acetonitrile SCHEMBL9174267 0.88 LOXL2 (0.50) APPLOXL2ALDH1A1CYP2A6MAPT
SCHEMBL22270629 0.83 APP (0.47) MMP3KIF11APPLOXL2ABCB1
SCHEMBL14470303 0.83 GSK3B (0.56) APPALDH1A1CA1CA2CA9
SCHEMBL23742234 0.83 SAE1 (0.62) APPLOXL2ALDH1A1CYP2A6MAPT
SCHEMBL25546850 0.81 MMP3 (0.56) MMP3KIF11ABCB1ABCG2CA1
SCHEMBL12994058 0.81 APP (0.57) APPLOXL2ALDH1A1KDM4ELMNA
SCHEMBL14211448 0.81 CYP1B1 (0.61) APPLOXL2ALDH1A1CYP2A6MAPT
SCHEMBL21305525 0.81 KDM4E (0.61) APPLOXL2ALDH1A1CYP2A6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021156636-A1 TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY KING'S COLLEGE LONDON (GB) 2021-08-12 WO disclosed
US-9844535-B2 SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-12-19 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-10-26 US disclosed
US-9676771-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-06-13 US disclosed
US-9522881-B2 Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-12-20 US disclosed
US-20160102054-A1 HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2016-04-14 US disclosed
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) 2016-03-24 US disclosed
WO-2014186398-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2014-11-20 WO disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320870-A1 COMPOUNDS CBR3, CNR1, HCAR3 MMP3 2428/4885KIF11 2589/4885APP 3905/4885
US-20160102054-A1 HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) SRC, PTPRCAP, PTPRJ MMP3 4101/4885KIF11 2341/4885APP 4590/4885
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 MMP3 3604/4885KIF11 3997/4885APP 3690/4885
US-20100317646-A1 COMPOUNDS CBR3, CNR1, HCAR3 MMP3 2369/4885KIF11 2638/4885APP 3984/4885
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 MMP3 3604/4885KIF11 3997/4885APP 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.